Mesoblast Limited vs Direxion Daily Semiconductor Bear 3X Shares — how do they compare? Mesoblast Limited trades at $14.31 (market cap $1.75B), while Direxion Daily Semiconductor Bear 3X Shares trades at $34.77 (market cap $1.96B). The key difference: Mesoblast Limited and Direxion Daily Semiconductor Bear 3X Shares are close in size by market cap, and Mesoblast Limited is trading nearer its 52-week high, Direxion Daily Semiconductor Bear 3X Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Mesoblast Limited for 14 Days and Direxion Daily Semiconductor Bear 3X Shares for 11 Days on average.
| MESO | SOXS | |
|---|---|---|
Market Cap | $1.75B | $1.96B |
Volume | 239,027 | 113,512,541 |
Sector | Health | Leveraged / Inverse |
52-Week High | $20.96 | $988.00 |
52-Week Low | $13.19 | $29.62 |
Typical Hold Time | 14 Days | 11 Days |
Enterprise Value | $1.83B | — |
Signals from Pluang's Aura AI — not financial advice
MESO trades at $13.94, up 2.42% with bearish technical signals from moving averages. The company reported substantial revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant operational milestones. Cash position remains strong at $161.16 million, though debt levels require monitoring.
While MESO shows promising revenue growth and pipeline progress, persistent losses and negative ROE present fundamental challenges. Analyst consensus leans bullish with 45% buy ratings, but technical indicators suggest near-term caution. The stock offers speculative growth potential contingent on successful commercialization and path to profitability.
SOXS, a leveraged inverse ETF tracking the semiconductor sector, trades at $34.12, up 11.34% over 24 hours amid recent semiconductor stock weakness. Technical indicators are bearish overall, with moving averages signaling sell pressure, while oscillators are neutral. The fund executed a 1:10 stock split in July 2026 and has a dividend scheduled for September 2026. News highlights focus on volatility and tactical use, with articles noting surges during chip sell-offs.
The outlook for SOXS remains highly speculative, suitable only for short-term tactical trades due to its leveraged inverse structure and extreme volatility. Key risks include rapid erosion from semiconductor sector rebounds and structural decay. Investors should avoid long-term holdings, as persistent AI demand could trigger sharp losses.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →SOXS is a leveraged ETF that seeks daily investment results corresponding to 300% of the inverse (opposite) of the daily performance of the ICE Semiconductor Index. It is designed as a tactical tool for experienced traders to take a bearish (short) position on the semiconductor sector. Due to the effects of compounding and leverage, SOXS is intended to be held for a single day and is not suitable for long-term investment.
Read more on SOXS →